1.00
-0.01 (-0.99%)
-0.01 (-0.99%)
Upgrade to Real-Time
Regular Market
Volume | 143,522 |
|
|||||
News | - | ||||||
Day High | 1.05 | Low High |
|||||
Day Low | 0.9985 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
HOOKIPA Pharma Inc | HOOK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.00 | 0.9985 | 1.05 | 1.01 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
413 | 143,522 | $ 1.02 | $ 145,940 | - | 0.72 - 3.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:00:01 | 658 | $ 1.00 | USD |
HOOKIPA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 54.72M | 54.72M | 46.44M | $ 18.45M | $ - | -2.30 | -0.60 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 0.80% |
HOOKIPA Pharma News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HOOK Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.99 | 1.05 | 0.96 | 0.9963107 | 207,209 | 0.01 | 1.01% |
1 Month | 0.872 | 1.10 | 0.8352 | 0.9755245 | 214,491 | 0.128 | 14.68% |
3 Months | 1.26 | 1.30 | 0.72 | 0.943869 | 326,044 | -0.26 | -20.63% |
6 Months | 1.47 | 1.77 | 0.72 | 1.21 | 632,664 | -0.47 | -31.97% |
1 Year | 1.38 | 3.05 | 0.72 | 1.97 | 2,120,188 | -0.38 | -27.54% |
3 Years | 12.16 | 20.00 | 0.72 | 3.00 | 820,589 | -11.16 | -91.78% |
5 Years | 14.00 | 20.00 | 0.72 | 3.17 | 668,819 | -13.00 | -92.86% |
HOOKIPA Pharma Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |